Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Takeda’s Entrepreneurship Scheme Attracts 30 Proposals
October 20, 2017
- Boehringer, Nagoya City Univ. Collaborate on Diabetic Retinopathy Research
October 19, 2017
- Astellas, US Nonprofit Join Forces to Discover TB Drugs
October 19, 2017
- Takeda, HemoShear Link Up in Drug Discovery for Liver Diseases
October 19, 2017
- Daiichi Sankyo, Saitama Medical Univ. Launch AMED-Funded Research on FOP Therapy
October 19, 2017
- Daiichi Sankyo in Exosome Research Deal with NCC, Devices Makers
October 19, 2017
- Kyowa Kirin Eyes US Resubmission for Nouriast Next Year
October 18, 2017
- Bayer Files Long-Acting Hemophilia A Treatment in Japan
October 18, 2017
- Otsuka Seeks Japan Approval of Alcohol Dependence Med Nalmefene
October 18, 2017
- AZ’s Ex-Japan Chief Fredrickson Picked as Global Head of Oncology
October 18, 2017
- Durvalumab Improves PFS in Japanese NSCLC Patients
October 17, 2017
- Tagrisso Significantly Extends PFS in Japanese EGFRm NSCLC Patients
October 17, 2017
- Nobelpharma Plans to File Sakigake-Designated Topical Sirolimus; Application Expected Later this Month
October 17, 2017
- Japan’s Oncology Market Estimated to Reach Over 1.4 Trillion Yen in 2025: Fuji Keizai
October 17, 2017
- Ethical Drug Sales Up 2.2% in August, Keytruda Upbeat: Crecon
October 17, 2017
- Naldemedine Now Available in US: Shionogi
October 16, 2017
- Takeda Looks to House 3,000 Researchers at Shonan Innovation Park, Create Fund by March
October 16, 2017
- Eisai to Acquire Marketing Authorization for Kolbet from Toyama Chemical on Jan. 1
October 16, 2017
- Novartis Not to Conduct Additional Japan Study of Ribociclib, While PIb Study Underway in Asian Countries including Japan
October 16, 2017
- Sanwa Kagaku to Reduce 150 Jobs as Part of Suzuken Group’s SGA Cost Cutting Efforts
October 16, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…